Chou Y K, Henderikx P, Vainiene M, Whitham R, Bourdette D, Chou C H, Hashim G, Offner H, Vandenbark A A
Department of Neuroimmunology Research, Veterans Affairs Medical Center, Portland, OR 97201.
J Neurosci Res. 1991 Feb;28(2):280-90. doi: 10.1002/jnr.490280215.
Several recently discovered lines of evidence support the involvement of myelin basic protein (BP)-specific T cells in multiple sclerosis (MS). To identify potentially relevant immunodominant T cell epitopes, human BP (Hu-BP)-reactive T cell lines were selected from MS and normal donors and tested for reactivity to cleavage fragments and synthetic peptides of Hu-BP. The MS T cell lines responded to more Hu-BP epitopes than did normal lines, showing biased recognition of the N terminal half of the molecule, and one region in the C terminal half, suggesting increased sensitization to BP. The MS lines also differed from normal lines in their decreased percentage of CD8+ T cells. One hundred nine T cell clones isolated from these lines confirmed the reactivity pattern of the lines but did not reflect the mixed phenotype, since all but three clones tested were CD4+. T cell clones from HLA-DR2 homozygous donors responded to a variety of epitopes, indicating that this molecule was permissive in its ability to restrict T cell responses. Other epitopes, including the immunodominant 149-170 sequence, were restricted by several different major histocompatibility complex (MHC) molecules from both MS and normal donors. T cell receptor (TCR) V gene products could be identified on six of 38 clones tested using monoclonal antibodies. From one HLA-DR2 homozygous donor, four of eight clones utilized V beta 5.2 in response to different BP epitopes, providing initial support for the preferential use of a limited set of V region genes in the human response to BP. Preferential TCR V gene use in MS patients would provide the rationale to regulate selectively BP-reactive T cells through immunity directed at the TCR and thus test for the first time the hypothesis that BP-reactive T cells play a critical role in the pathogenesis of MS.
最近发现的几条证据支持髓鞘碱性蛋白(BP)特异性T细胞参与多发性硬化症(MS)。为了确定潜在相关的免疫显性T细胞表位,从MS患者和正常供体中筛选出人BP(Hu - BP)反应性T细胞系,并检测其对Hu - BP裂解片段和合成肽的反应性。与正常T细胞系相比,MS T细胞系对更多的Hu - BP表位有反应,表现出对该分子N端一半区域以及C端一半区域中一个区域的偏向性识别,提示对BP的致敏性增加。MS T细胞系与正常T细胞系的另一个差异在于其CD8 + T细胞百分比降低。从这些细胞系中分离出的109个T细胞克隆证实了细胞系的反应模式,但未反映出混合表型,因为除3个克隆外,所有检测的克隆均为CD4 +。来自HLA - DR2纯合供体的T细胞克隆对多种表位有反应,表明该分子在限制T细胞反应的能力方面较为宽松。其他表位,包括免疫显性的149 - 170序列,受到来自MS患者和正常供体的几种不同主要组织相容性复合体(MHC)分子的限制。使用单克隆抗体在38个检测的克隆中的6个上鉴定出了T细胞受体(TCR)V基因产物。来自一名HLA - DR2纯合供体的8个克隆中有4个在对不同BP表位的反应中利用了Vβ5.2,这为人类对BP反应中有限的一组V区基因的优先使用提供了初步支持。MS患者中TCR V基因的优先使用将为通过针对TCR的免疫选择性调节BP反应性T细胞提供理论依据,从而首次检验BP反应性T细胞在MS发病机制中起关键作用的假说。